缬沙坦对冠心病患者心功能和炎性因子水平的影响研究

Influence of valsartan on cardiac function and levels of inflammatory factors in patients with coronary heart disease

目的:分析缬沙坦对冠心病患者心功能和炎性因子水平的影响。方法:我院183例冠心病患者被分为常规治疗组(101例)和联合治疗组(82例,在常规治疗组基础上加用缬沙坦),两组均治疗6个月。观察比较两组治疗前后LVEF、左室收缩末期内径(LVESd)、左室舒张末期内径(LVEDd)、左室后壁厚度(LVPWT)、N末端B型利钠肽前体(NT-proBNP)和高敏C反应蛋白(hsCRP)水平。结果:治疗6个月后,与常规治疗组比较,联合治疗组LVEF[(42.62±0.89)%比(48.62±0.87)%]显著升高,LVESd[(36.04±0.34)mm比(30.12±0.26)mm]、LVEDd[(58.24±0.43)mm比(48.29±0.36)mm]、LVPWT[(10.54±0.51)mm比(8.98±0.49)mm]、NT-proBNP[(294.50±14.63)pg/ml比(176.40±10.46)pg/ml]和hsCRP[(2.42±0.32)mg/L比(1.89±0.36)mg/L]水平均显著降低,P均=0.001。结论:缬沙坦可显著抑制冠心病患者的心室重构和炎性反应,有助于改善心功能。

Objective:To analyze influence of valsartan on cardiac function and levels of inflammatory factors in patients with coronary heart disease(CHD).Methods:The 183 CHD patients in our hospital were divided into routine treatment group(n=101)and combined treatment group(n=82,received valsartan based on routine treatment group),both groups were treated for six months.LVEF,left ventricular end-systolic dimension(LVESd),left ventricular end-diastolic dimension(LVEDd),left ventricular posterior wall thickness(LVPWT),levels of N terminal pro brain natriuretic peptide(NT-proBNP)and high sensitive C reactive protein(hsCRP)were observed and compared between two groups before and after treatment.Results:After six-month treatment,compared with routine treatment group,there was significant rise in LVEF [(42.62±0.89)% vs.(48.62±0.87)%],and significant reductions in LVESd [(36.04±0.34)mm vs.(30.12±0.26)mm],LVEDd [(58.24±0.43)mm vs.(48.29±0.36)mm],LVPWT [(10.54±0.51)mm vs.(8.98±0.49)mm],levels of NT-proBNP [(294.50±14.63)pg/ml vs.(176.40±10.46)pg/ml]and hsCRP [(2.42±0.32)mg/L vs.(1.89±0.36)mg/L]in combined treatment group,P=0.001 all.Conclusion:Valsartan can significantly inhibit ventricular remodeling and inflammatory response,and contribute to improving cardiac function in CHD patients.